What was filed
Jagsonpal Pharmaceuticals told BSE and NSE it has entered into a Share Purchase Agreement to acquire 85% of the paid-up equity capital of Aequitas Healthcare Private Limited, a Mumbai company that sells and distributes pharmaceutical products to hospitals. The current directors of Aequitas will retain the remaining 15% and continue to be associated with the business. The filing states the transaction does not fall within related-party transactions, and that the promoter and promoter group have no interest in the target.
The rationale disclosed
Per the filing, the acquisition aligns with Jagsonpal's stated objective of gaining access to the hospital channel and institutional doctor network for its products, which the company said reduces the time needed to build such relationships organically. Jagsonpal describes its own portfolio as focused on gynaecology, orthopaedics and dermatology, sold largely through a retail prescription model; management framed the move as an entry into the hospital segment. The consideration is entirely in cash and, the company said, funded from internal accruals.
Timing and approvals
The company stated that no governmental or regulatory approvals are required, and that completion is expected by 15 July 2026, subject to fulfilment of the conditions in the SPA. The filing named J Sagar & Associates as legal advisor to Jagsonpal and Noverra Partners as advisor to Aequitas.